SARS-CoV-2 vaccines in development

Krammer, Florian·2020·Nature
DOI 10.1038/s41586-020-2798-3

Cited by (1,004)

Items 901–1,000 of 1,004

  1. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern
    Jiayu Xu, Yuexiu Zhang, Panke Qu, Mohamed M. Shamseldin, Sung Joon Yoo, Jack Misny, Ilada Thongpan, Mahesh KC, Jesse M. Hall, John Parker Evans et al. · 2023 · Proceedings of the National Academy of Sciences
  2. Sustainable performance evaluation of pharmaceutical companies: sustainable balanced scorecard and hybrid MCDM approach
    Deqiang Deng, Jiayang Zhang, Jingyi Wang, Xiuran Zong · 2025 · Frontiers in Public Health
  3. Coronavirus Disease (COVID-19)
    Madhusudan Hiraman Fulekar, Geetika Madan Patel, Ashita Rai · 2025 · Springer eBooks
  4. Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19
    Waiting Tai, Michael Y.T. Chow, Rachel Yoon Kyung Chang, Patricia Tang, Igor Gonda, Robert Bruce MacArthur, Hak‐Kim Chan, Philip Chi Lip Kwok · 2021 · Pharmaceutics
  5. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis
    Ling Zuo, Guangyu Ao, Yushu Wang, Ming Gao, Xin Qi · 2021 · Journal of Infection
  6. An Overview of COVID-19 Vaccine Safety and Post-marketing Surveillance Systems
    Manal M. Younus, Ali Azeez Al‐Jumaili · 2021 · INNOVATIONS in pharmacy
  7. COVID Vaccination in Athletes and Updated Interim Guidance on the Preparticipation Physical Examination During the SARS-Cov-2 Pandemic
    Dusty Marie Narducci, Alex Benjamin Diamond, David T. Bernhardt, William Oliver Roberts · 2021 · Clinical Journal of Sport Medicine
  8. Nasal therapy—The missing link in optimising strategies to improve prevention and treatment of COVID-19
    Norman Arthur Ratcliffe, Helena Carla Castro, Izabel Christina Nunes de Palmer Paixão, Victor Gustavo Oliveira Evangelho, Patrı́cia Azambuja, Cicero Brasileiro de Mello Neto · 2021 · PLoS Pathogens
  9. Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients
    Ganesh Korishettar, Prashanth Chikkahonnaiah, SubbaRao V. Tulimilli, Siva Dallavalasa, Shashidhar H. Byrappa, SubbaRao V. Madhunapantula, Ravindra P. Veeranna · 2022 · Vaccines
  10. Peptide mimotopes to emulate carbohydrates
    Teruhiko Matsubara · 2022 · Chemical Society Reviews
  11. Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses
    Diana Laura Pacheco-Olvera, Stephanie Saint Remy-Hernández, María Guadalupe García-Valeriano, Tania Rivera-Hernández, Constantino III Roberto López-Macías · 2022 · Archives of Medical Research
  12. Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals
    Ambra Natalini, Sonia Simonetti, Carmel Sher, Ugo D’Oro, Adrian Hayday, Francesca Di Rosa · 2022 · International Journal of Molecular Sciences
  13. Durability of humoral and cell‐mediated immune response after SARS‐CoV‐2 mRNA vaccine administration
    Anastasiya Mihaylova, Spaska Lesichkova, Marta Petrova Baleva, Milena Krasimirova Nikolova-Vlahova, Todor Kundurzhiev, Alexander Kolevski, Elissaveta Jordanova Naumova · 2022 · Journal of Medical Virology
  14. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice
    Mariam Maltseva, Yannick Galipeau, Tyler Milston Renner, Lise Deschatelets, Yves Durocher, Bassel Akache, Marc‐André Langlois · 2022 · Vaccines
  15. SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues
    Chukwunonso K. Nwabufo, Md. Tozammel Hoque, Lily Yip, Maliha Khara, Samira Mubareka, Michael S. Pollanen, Reina Bendayan · 2023 · Frontiers in Pharmacology
  16. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
    Steven C. Wall, Naveenchandra Suryadevara, Changil Kim, Andrea R. Shiakolas, Clinton M. Holt, Emma B Irbe, Perry T. Wasdin, Yukthi P. Suresh, E. Binshtein, Elaine C. Chen et al. · 2023 · Cell Reports Medicine
  17. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model
    Devanshi R. Patel, Allen M. Minns, Derek G. Sim, Cassandra J. Field, Abigail E. Kerr, Talia A. Heinly, Erin Luley, Randall M. Rossi, Carol M. Bator, Ibrahim M. Moustafa et al. · 2024 · Microbiology Spectrum
  18. Maximization of Open Hospital Capacity under Shortage of SARS-CoV-2 Vaccines—An Open Access, Stochastic Simulation Tool
    Wolfram A. Bosbach, Martin Heinrich, Rainer Kolisch, Christian Heiß · 2021 · Vaccines
  19. SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
    Ralf Duerr, Keaton M. Crosse, Ana M. Valero-Jimenez, Meike Dittmann · 2021 · Microorganisms
  20. De novo Design of SARS-CoV-2 Main Protease Inhibitors
    Nynke A. Vepřek, Zisis V. Peitsinis, Yingkai Zhang, Dirk H. Trauner, Christian Fischer, Klaus-Peter Ruehmann, Chao Yang, Jessica N. Spradlin, Dustin Dovala, Daniel K. Nomura · 2021 · Synlett
  21. Supporting doctors' well‐being and resilience during COVID‐19: A framework for rapid and rigorous intervention development
    Kathrine Gibson Smith, Kathryn B Cunningham, Joanne Elizabeth Cecil, Anita H. Laidlaw, Patrick Cairns, Gillian Marion Scanlan, Tricia Tooman, Gill Aitken, Julie Ferguson, Lisi J Gordon et al. · 2021 · Applied Psychology Health and Well-Being
  22. COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI)
    Ludger Klimek, Oliver Pfaar, Eckard H. Hamelmann, Jörg Kleine‐Tebbe, Christian Taube, Martin Wagenmann, Thomas Werfel, Randolf Brehler, Natalija Novak, Norbert Karl Mülleneisen et al. · 2021 · Allergologie select
  23. Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
    Nawamin Sa-nguanmoo, K. Namdee, M. Khongkow, Uracha Ruktanonchai, Yong-Xiang Zhao, Xing-Jie Liang · 2021 · Nano Reseach
  24. Tuftsin: A Natural Molecule Against SARS-CoV-2 Infection
    Jiahao Huang, Jing Wang, Yan Li, Ziyuan Wang, Ming Chu, Yuedan Wang · 2022 · Frontiers in Molecular Biosciences
  25. Looking for SARS-CoV-2 Therapeutics Through Computational Approaches
    Marian Vincenzi, Flavia Anna Mercurio, Marilisa Leone · 2022 · Current Medicinal Chemistry
  26. Therapeutic strategies targeting synovial cells to treat osteoarthritis
    Fanfan Li, Jagadeesh Kumar Venkatesan, Henning Madry, Magali Cucchiarini · 2025 · Biomedicine & Pharmacotherapy
  27. Neurologic Safety Monitoring of COVID-19 Vaccines
    Kiran Teresa Thakur, Samantha Epstein, Amanda E. Bilski, Alanna M. Balbi, Amelia K. Boehme, Thomas H. Brannagan, Sarah Flanagan Wesley, Claire Riley · 2021 · Neurology
  28. Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay
    Hui Zhang, Xingtian Liu, Qingzhi Liu, Hongshuang Mei, Yashu Wang, Gang Cui, Shuping Zhao · 2022 · International Journal of Infectious Diseases
  29. Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction
    Ruhar Singh, Abhijeet Kumar, Jitendra Subhash Rane, Rajni Khan, Garima Tripathi, Amrendra K. Ajay, Amresh Prakash, Shashikant Ray · 2022 · Scientific Reports
  30. Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations
    Rachel Y. Gao, Christine M. Riley, Evan Toth, Rebecca H. Blair, Megan N. Gerold, Caitlin McCormick, Amber W. Taylor, Tianjing Hu, Kathy L. Rowlen, Erica D. Dawson · 2022 · Vaccines
  31. Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants
    Sumin Han, Panjae Lee, Hyo‐Jick Choi · 2023 · Pharmaceutics
  32. Interaction of the III-As monolayer with SARS-CoV-2 biomarkers: implications for biosensor development
    Sudipta Saha, Deb Indronil Sajib, Md. Kawsar Alam · 2024 · Physical Chemistry Chemical Physics
  33. Synthesis of Novel 7-Phenyl-2,3-Dihydropyrrolo[2,1-b]Quinazolin-9(1H)-ones as Cholinesterase Inhibitors Targeting Alzheimer’s Disease Through Suzuki–Miyaura Cross-Coupling Reaction
    Davron Turgunov, Lifei Nie, Azizbek Nasrullaev, Zarifa Murtazaeva, Bianlin Wang, Dilafruz K. Kholmurodova, Rustamkhon Kuryazov, Jiangyu Zhao, Khurshed A. Bozorov, Haji Akber Aisa · 2025 · Molecules
  34. Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes
    Sunil Bhopal, Bayanne Olabi, Raj S. Bhopal · 2021 · Public Health
  35. From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic
    Mohammad Zarei, Karim Rahimi, Kambiz Hassanzadeh, Mohammad Abdi, Vahedeh Hosseini, Ali Fathi, Karim Kakaei · 2021 · Environmental Research
  36. Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing
    Rosa Camacho-Sandoval, Alejandro Nieto-Patlán, Gregorio Carballo‐Uicab, Alejandra Montes-Luna, María del Carmen Jiménez Martínez, Luis Vallejo‐Castillo, Edith González‐González, Hugo Iván Arrieta-Oliva, Keyla Gómez-Castellano, Omar U. Guzmán-Bringas et al. · 2021 · Diagnostics
  37. Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients
    Bernadette Crescenzo-Chaigne, Sylvie Behillil, Vincent Enouf, Nicolas Escriou, Stéphane Pêtres, Marie Noëlle Ungeheuer, Jade Ghosn, Sarah Tubiana, Lila Bouadma, Sylvie van der Werf et al. · 2021 · Journal of Clinical Virology Plus
  38. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
    Fabrizia Valleriani, Elisa Mancuso, Giacomo Vincifori, Liana Teodori, Lisa Di Marcantonio, Massimo Spedicato, Alessandra Leone, Giovanni Savini, Daniela Morelli, Barbara Bonfini et al. · 2021 · Viruses
  39. Discrimination and isolation of the virus from free RNA fragments for the highly sensitive measurement of SARS-CoV-2 abundance on surfaces using a graphene oxide nano surface
    Hyun Jin Yoo, Yun Guang Li, Wen Ying Cui, Wonseok Chung, Yong‐Beom Shin, Kim Ys, Changyoon Baek, Junhong Min · 2021 · Nano Convergence
  40. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
    José Luís Piñana, Lourdes Vázquez, Rodrigo Martino, Rafael de la Cámara, Anna Maria Sureda, Rebeca Rodríguez‐Veiga, Ana Garrido, Jorge Sierra, Josep‐María Ribera, Anna Torrent et al. · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
  41. Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations
    Sanjay K. Murthy, M Ellen Kuenzig, Joseph W. Windsor, Jean‐Eric Ghia, Anne Marie Griffiths, Remo Panaccione, Cynthia H. Seow, Eric Ian Benchimol, Charles Noah Bernstein, Alain Bitton et al. · 2021 · Journal of the Canadian Association of Gastroenterology
  42. Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers
    Filippos Filippatos, Elizabeth‐Barbara Tatsi, Charilaos Dellis, Nick Dessypris, Vasiliki Syriopoulou, Athanasios G. Michos · 2021 · Human Vaccines & Immunotherapeutics
  43. Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization
    Marcílio Jorge Fumagalli, Luíza Antunes de Castro-Jorge, Thais Fernanda de Campos Fraga‐Silva, Patrick Orestes de Azevedo, Carlos Fabiano Capato, Bruna Amanda da Cruz Rattis, Natália Satchiko Hojo-Souza, Vitor Gonçalves Floriano, Júlia Teixeira de Castro, Simone Gusmão Ramos et al. · 2021 · Viruses
  44. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
    Debashree Chatterjee, Alexandra Tauzin, Annemarie Laumaea, Shang Yu Gong, Yuxia Bo, Aurélie Guilbault, Guillaume Goyette, Catherine Bourassa, Gabrielle Gendron‐Lepage, Halima Medjahed et al. · 2022 · Viruses
  45. Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor
    Hemant Suryavanshi, Raju D. Chaudhari, Vishakha Patil, Swapan Majumdar, Sudhan Debnath, Goutam K. Biswas · 2022 · DARU Journal of Pharmaceutical Sciences
  46. Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic
    Rasmi V. Morajkar, Akhil Sree Kumar, Rohan Keshav Kunkalekar, Amit Ashok Vernekar · 2022 · Biosafety and Health
  47. mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks and Coverage.
    Abdulqadir J. Nashwan, Mohamed A. Yassin, Ashraf Tawfik Soliman, Vincenzo De Sanctis, Mohamed Ibrahim · 2022 · PubMed Central
  48. Intensity of Humoral Immune Responses, Adverse Reactions, and Post-Vaccination Morbidity after Adenovirus Vector-Based and mRNA Anti-COVID-19 Vaccines
    Ioanna Voulgaridi, Styliani Sarrou, Katerina Dadouli, Athanasia-Marina Peristeri, Asimina Nasika, Ilias Onoufriadis, Maria A. Kyritsi, Lemonia Anagnostopoulos, Aikaterini Theodoridou, Ioanna Avakian et al. · 2022 · Vaccines
  49. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project
    Valéria Valim, Olindo Assis Martins‐Filho, Maria da Penha Gomes Gouvea, Luiz Antônio Bastos Camacho, Daniel Antunes Maciel Villela, Sheila Maria Barbosa de Lima, Adriana de Souza Azevedo, Lauro Ferreira da Silva Pinto Neto, Carla Magda Allan Santos Domingues, Nésio Fernandes de Medeiros et al. · 2022 · Frontiers in Immunology
  50. Factors associated with reluctancy to acquire COVID-19 vaccination: A cross-sectional study in Shiraz, Iran, 2022
    Najmeh Maharlouei, Parisa Hosseinpour, Amirhossein Erfani, Reza Shahriarirad, Hadi Raeisi Shahraki, Abbas Rezaianzadeh, Kamran Bagheri Lankarani · 2022 · PLoS ONE
  51. Biophysical characterization of the structure of a SARS-CoV-2 self-amplifying RNA (saRNA) vaccine
    Daniel P. Myatt, Lewis Wharram, Charlotte Graham, John Liddell, Harvey Branton, Claire L. Pizzey, Nathan Philip Cowieson, Robert P. Rambo, Robin J. Shattock · 2023 · Biology Methods and Protocols
  52. Architecture of the SARS-CoV-2-specific T cell repertoire
    Ksenia V. Zornikova, Saveliy Andreevich Sheetikov, Alexander Yu Rusinov, Rustam N. Iskhakov, Боголюбова Аполлинария Васильевна · 2023 · Frontiers in Immunology
  53. Development of an Effective Neutralizing Antibody Assay for SARS-CoV-2 Diagnosis
    Zhigang Liu, Jiahui Liang, Hangzhan Hu, Mengli Wu, Jingjing Ma, Ziwei Ma, Jianing Ji, Hengyi Chen, Xiaoquan Li, Zhizeng Wang et al. · 2023 · International Journal of Nanomedicine
  54. Perspectives and trends in advanced optical and electrochemical biosensors based on engineered peptides
    Junjie Xia, Suyun Zhong, Xiaojun Hu, Kwangnak Koh, Hongxia Chen · 2023 · Microchimica Acta
  55. Vaccine Molecule Design Based on Phage Display and Computational Modeling against Rhabdovirus
    Yuying Zheng, Liang Zhao, Xuefeng Wei, Tian-Zi Sun, Feifan Xu, Gao‐Xue Wang, Bin Zhu · 2024 · The Journal of Immunology
  56. SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition
    Claudia Fischer, Edith Willscher, Lisa Paschold, Cornelia Gottschick, Bianca Klee, Sophie Diexer, Lidia Bosurgi, Jochen Dutzmann, Daniel Sedding, Thomas Frese et al. · 2024 · npj Vaccines
  57. What Gastroenterologists Should Know About COVID-19 Vaccines
    Stacey C. Rolak, Mary S. Hayney, Francis A. Farraye, Jonathan L. Temte, Freddy Caldera · 2021 · Clinical Gastroenterology and Hepatology
  58. A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters
    Bao-Zhong Zhang, Xiaolei Wang, Shuo-Feng Yuan, Wenjun Li, Y. Dou, V. Poon, C. Chan, Jian-Piao Cai, K. Chik, K. Tang et al. · 2021 · Emerging Microbes and Infections
  59. CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens
    Jingen Zhu, Neeti Ananthaswamy, Swati Jain, Himanshu Batra, Weichun Tang, Venigalla Basaveswara Rao · 2021 · Methods in molecular biology
  60. Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines
    Connor Bamford, Lindsay Broadbent, Elihú Aranday-Cortés, Mary McCabe, James Patrick McKenna, David Courtney, Olivier Touzelet, Ahlam Ali, Grace C. Roberts, Guillermo López–Campos et al. · 2022 · Viruses
  61. The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate
    Bo‐Kyoung Jung, Yong Hee An, Jinju Jang, Joo Hee Jeon, Sung Hoon Jang, Hyun Gyung Jang · 2022 · PLoS ONE
  62. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review
    Setare Adibzadeh, Shahin Amiri, Giti Esmail Nia, Maryam Rezakhani Taleghani, Zahra Kohanrooz Bijarpas, Neda Maserat, Amirhosein Maali, Mehdi Azad, Abbas Behzad‐Behbahani · 2022 · Gene Reports
  63. Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
    Mandy Schwarze, Andor Krizsan, Alexandra Brakel, Fabian Pohl, Daniela Volke, Ralf Hoffmann · 2022 · Frontiers in Immunology
  64. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
    Miguel Ángel Muñoz-Alía, Rebecca A. Nace, Baskar Balakrishnan, Lianwen Zhang, Nandakumar Packiriswamy, Gagandeep Singh, Prajakta Warang, Ignacio Mena, Riya Narjari, Rianna Vandergaast et al. · 2024 · mBio
  65. Data-driven estimate of SARS-CoV-2 herd immunity threshold in populations with individual contact pattern variations
    Dan Z. Lu, Alberto Aleta, Marco Ajelli, Romualdo Pastor‐Satorras, Alessandro Vespignani, Yamir Moreno · 2021 · medRxiv
  66. The New SARS-CoV-2 Variants and Their Epidemiological Impact in Mexico
    R. García-López, E. Laresgoiti-Servitje, R. Lemus-Martin, A. Sánchez-Flores, Carlos Sanders‐Velez · 2022 · mBio
  67. Characteristics of unvaccinated and vaccinated critically ill COVID-19 patients in calabria region (Italy): A retrospective study
    Andrea Bruni, Federico Longhini, Sebastiano Macheda, Eugenio Biamonte, Pino Pasqua, Giuseppe Neri, Maria Laura Guzzo, Eugenio Garofalo, Calabria COVID-ICU Network authors · 2022 · Frontiers in Medicine
  68. What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?
    Hui Juan Lu, Zhipeng Cheng, Yu Hu, Liang V. Tang · 2023 · Biology
  69. Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection
    Shuang Mei, Yunting Zou, Su Jiang, Xue Lü, Yuting Wang, Jing Dong J Han, Peng Yang, Miaomiao Niu, Jindong Li, Kai Yuan et al. · 2023 · European Journal of Medicinal Chemistry
  70. Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
    Keda Chen, Ling Zhang, Zhongbiao Fang, Jiaxuan Li, Chaonan Li, Wancheng Song, Zhi‐wei Huang, Ruyi Chen, Yanjun Zhang, Jianhua Li · 2023 · Frontiers in Immunology
  71. The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
    Jingjing Song, Yujun Zhang, Chulin Zhou, Jianhao Zhan, Xifu Cheng, Haoyu Huang, Shengxun Mao, Zhen Zong · 2024 · International Immunopharmacology
  72. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants
    Hao Zhou, Ping Leng, Yang Wang, Kaiwen Yang, Chen Li, David M. Ojcius, Pengfei Wang, Shibo Jiang · 2024 · 中国科学通报：英文版
  73. Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic”
    Florian Krammer, Jacqueline M. Katz, Othmar G. Engelhardt, Diane J. Post, Paul C. Roberts, Sheena G. Sullivan, Stephen Mark Tompkins, Christopher Chiu, Stacey Schultz‐Cherry, Rebecca Jane Cox · 2024 · Influenza and Other Respiratory Viruses
  74. Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models
    Irene González‐Domínguez, Adam Abdeljawad, Tsoi Ying Lai, Marta Boza, Stephen McCroskery, Nicholas Lemus, Stefan Slamanig, Gagandeep Singh, Prajakta Warang, Temima Yellin et al. · 2025 · Frontiers in Immunology
  75. Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2
    Wout Bittremieux, Charlotte Adams, Kris Laukens, Pieter C. Dorrestein, Nuno Bandeira · 2021 · Journal of Proteome Research
  76. Updates on the coronavirus disease 2019 vaccine and consideration in children
    Hyun Mi Kang, Eun Hwa Choi, Yae‐Jean Kim · 2021 · Korean Journal of Pediatrics
  77. COVID‐19 vaccines: what do we know so far?
    Paraminder Dhillon, Daniel Martin Altmann, Victoria H. Male · 2021 · FEBS Journal
  78. Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternal—Not Identical—Twins
    Theodore Earl Warkentin · 2021 · Thrombosis and Haemostasis
  79. The Recent Updates on Approaches and Clinical Trials Status of Covid-19 Vaccines Developed Globally
    Sachin Chaudhary, Abdel‐Nasser El‐Shorbagi, Ramesh Kumar Gupta, Amit Kumar · 2021 · Biomedical & Pharmacology Journal
  80. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic
    Rhodri Harfoot, Blair Lawley, Leonor C. Hernández, Joanna Kuang, Jenny Grant, Jackson M. Treece, Sharon Lequeux, Robert C. Day, Susan J. Jack, Jo‐Ann L. Stanton et al. · 2022 · Viruses
  81. VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern
    Kyle Lee O’Donnell, Tylisha Gourdine, Paige Fletcher, Kyle Shifflett, Wakako Furuyama, Chad S. Clancy, Andrea Marzi · 2022 · Vaccines
  82. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity
    A. Kuzmina, Seraj Wattad, Stanislav Engel, Elli Rosenberg, R. Taube · 2022 · Viruses
  83. Nonhuman primate models for evaluation of SARS-CoV-2 vaccines
    Jessica Anne Neil, Maryanne Griffith, Dale Ian Godfrey, Damian F. J. Purcell, Georgia Deliyannis, David Charles Jackson, Steve Rockman, Kanta Subbarao, Terry M. Nolan · 2022 · Expert Review of Vaccines
  84. Materials‐based vaccines for infectious diseases
    Bo Yang, Hua Wang · 2022 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
  85. Atomistic insights into the binding of SARS-CoV-2 spike receptor binding domain with the human ACE2 receptor: The importance of residue 493
    Camryn Carter, Justin Airas, Carol A. Parish · 2022 · Journal of Molecular Graphics and Modelling
  86. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
    Anna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, Pavel Marichal‐Gallardo, Kenn Holmbeck, Anne Finne Pihl, Carlota Fernandez-Antunez, Garazi Peña Alzua, Katrine Top Hartmann, Long V. Pham et al. · 2023 · iScience
  87. Baculovirus-expressed self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induce protective immunity in mice
    Xingjian Liu, Haozhi Song, Jianmin Jiang, Xintao Gao, Yongzhu Yi, Yuting Shang, Jialei Li, Dan Li, Zhen Zeng, Yinü Li et al. · 2023 · Process Biochemistry
  88. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
    Fernando L. Silveira, Mariana Rivera-Patron, Nikita Deshpande, Soledad Sienra, Jackeline Checa, María Moreno, Jose Alejandro Chabalgoity, Samuel Paulo Cibulski, Mariana Baz · 2023 · Frontiers in Immunology
  89. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study
    Carol Ann Hitchon, Christine Mesa, Charles Noah Bernstein, Ruth Ann Marrie, Catherine M. Card, Sheila F. O’Brien, John Kim · 2023 · BMJ Open
  90. The forerunners and successful partnerships behind the BioNTech mRNA vaccine
    Ilkin Aygün, Jan Barciszewski · 2023 · Journal of Applied Genetics
  91. Dual‐Antigen‐Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications
    Fangjie Chen, Mengmeng Zhang, Fengmin Yang, Lu Wang, Jinyao Liu, Junqiu Liu, Yan Pang · 2023 · Small
  92. RNA Vaccines for COVID-19
    Chien-Jung Lin, Robert P. Mecham, Douglas L. Mann · 2020 · JACC Basic to Translational Science
  93. Immune response and possible therapeutics in COVID-19
    Anindya Dutta, Ananya Roy, Laboni Roy, Samit Chattopadhyay, Subhrangsu Chatterjee · 2021 · RSC Advances
  94. Advanced microscopy technologies enable rapid response to SARS‐CoV ‐2 pandemic
    Mirko Cortese, Vibor Laketa · 2021 · Cellular Microbiology
  95. Severe acute respiratory syndrome (SARS) related coronavirus in bats
    Rong Geng, Peng Zhou · 2021 · Animal Diseases
  96. Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?
    Ilaria Campesi, Giorgio Racagni, Flavia Franconi · 2021 · Pharmaceuticals
  97. Cell-Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein
    Johannes Ruhnau, Valerian Grote, Mariana Juarez-Osorio, Dunja Bruder, Reza Mahour, Erdmann Rapp, Thomas Rexer, Udo Reichl · 2021 · Frontiers in Bioengineering and Biotechnology
  98. Aseptic Meningitis Following the Second Dose of Comirnaty Vaccination in an Adolescent Patient
    Joon Kee Lee · 2021 · The Pediatric Infectious Disease Journal
  99. Performance Characteristics of High-Throughput Serologic Assays for Severe Acute Respiratory Syndrome Coronavirus 2 with Food and Drug Administration Emergency Use Authorization
    Elitza S. Theel · 2021 · Clinics in Laboratory Medicine
  100. SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD
    Endah Puji Septisetyani, Pekik Wiji Prasetyaningrum, Khairul Anam, Adi Santoso · 2021 · Immune Network